eligibility_summary
Include: Adults 18–75 with IMWG-defined multiple myeloma, R/R or primary refractory, measurable disease, ECOG 0–2, adequate organ function, venous access. Exclude: other cancer <3 y, recent anti-cancer therapy/HSCT/surgery/live vaccine, CNS disease/involvement, WM/POEMS/AL, active viral/syphilis infection, severe allergy, major cardiac/systemic disease, GVHD, autoimmune neuro disease, recent steroids/immunosuppressants/cytokines, psychiatric/substance abuse, pregnancy/lactation.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: BCMA/GPRC5D double CAR-T, an autologous, genetically engineered T‑cell therapy. Mechanism: patient T cells are modified to express chimeric receptors that bind two myeloma antigens—BCMA (TNFRSF17) and GPRC5D—triggering CD3ζ/costimulatory signaling, T‑cell activation, cytokine release, and perforin/granzyme-mediated lysis, dual targeting aims to reduce antigen escape. Targets: relapsed/refractory multiple myeloma cells (malignant plasma cells) expressing BCMA and/or GPRC5D. Design: single‑arm study (China), 3×10^6–1×10^7 CAR+ cells/kg, endpoints focus on safety and efficacy.